| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | EyePoint Pharmaceuticals, Inc. | 3,095,136 | 6.1% | EDGAR |
| SC 13G | 2024-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | EyePoint Pharmaceuticals, Inc. | 2,522,704 | 5.6% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | EyePoint Pharmaceuticals, Inc. | 4,774,389 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-07 | ADAGE CAPITAL PARTNERS GP, L.L.C. | EyePoint Pharmaceuticals, Inc. | 4,466,420 | 9.2% | EDGAR |
| SC 13G/A | 2024-02-06 | FRANKLIN RESOURCES INC | EyePoint Pharmaceuticals, Inc. | 4,640,651 | 9.5% | EDGAR |
| SC 13G/A | 2023-12-14 | Cormorant Asset Management, LP | EyePoint Pharmaceuticals, Inc. | 6,038,235 | - | EDGAR |
| SC 13D/A | 2023-12-08 | EW Healthcare Partners, L.P. | EyePoint Pharmaceuticals, Inc. | 2,247,432 | 4.8% | EDGAR |
| SC 13G/A | 2023-09-11 | FRANKLIN RESOURCES INC | EyePoint Pharmaceuticals, Inc. | 4,130,137 | 11.8% | EDGAR |
| SC 13D/A | 2023-08-30 | EW Healthcare Partners, L.P. | EyePoint Pharmaceuticals, Inc. | - | - | EDGAR |
| SC 13G/A | 2023-05-01 | Cormorant Global Healthcare Master Fund, LP | EyePoint Pharmaceuticals, Inc. | 3,200,000 | - | EDGAR |
| SC 13G/A | 2023-02-14 | RA CAPITAL MANAGEMENT, L.P. | EyePoint Pharmaceuticals, Inc. | 3,408,706 | 10.0% | EDGAR |
| SC 13G/A | 2023-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | EyePoint Pharmaceuticals, Inc. | 3,411,210 | 10.0% | EDGAR |
| SC 13G/A | 2023-01-31 | FRANKLIN RESOURCES INC | EyePoint Pharmaceuticals, Inc. | 5,774,509 | 16.9% | EDGAR |
| SC 13G/A | 2022-02-11 | SUVRETTA CAPITAL MANAGEMENT, LLC | EyePoint Pharmaceuticals, Inc. | 3,482,109 | 10.0% | EDGAR |
| SC 13G/A | 2022-02-10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | EyePoint Pharmaceuticals, Inc. | 1,950,000 | 5.8% | EDGAR |
| SC 13G/A | 2022-02-03 | FRANKLIN RESOURCES INC | EyePoint Pharmaceuticals, Inc. | 4,947,165 | 14.6% | EDGAR |
| SC 13G | 2022-02-03 | FRANKLIN RESOURCES INC | EyePoint Pharmaceuticals, Inc. | 8,333,476 | 5.5% | EDGAR |
| SC 13G | 2021-08-13 | RA CAPITAL MANAGEMENT, L.P. | EyePoint Pharmaceuticals, Inc. | 1,606,859 | 5.6% | EDGAR |
| SC 13G | 2021-07-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | EyePoint Pharmaceuticals, Inc. | 1,595,164 | 5.6% | EDGAR |
| SC 13G | 2021-02-12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | EyePoint Pharmaceuticals, Inc. | 1,500,000 | 5.2% | EDGAR |